CN109789181A - 用于调节因子ix功能的组合物和方法 - Google Patents
用于调节因子ix功能的组合物和方法 Download PDFInfo
- Publication number
- CN109789181A CN109789181A CN201780059441.0A CN201780059441A CN109789181A CN 109789181 A CN109789181 A CN 109789181A CN 201780059441 A CN201780059441 A CN 201780059441A CN 109789181 A CN109789181 A CN 109789181A
- Authority
- CN
- China
- Prior art keywords
- variant
- factor
- substitution
- nucleic acid
- arg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662367321P | 2016-07-27 | 2016-07-27 | |
| US62/367,321 | 2016-07-27 | ||
| PCT/US2017/044104 WO2018022844A2 (en) | 2016-07-27 | 2017-07-27 | Compositions and methods for modulating factor ix function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109789181A true CN109789181A (zh) | 2019-05-21 |
Family
ID=61016739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780059441.0A Pending CN109789181A (zh) | 2016-07-27 | 2017-07-27 | 用于调节因子ix功能的组合物和方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11708570B2 (enExample) |
| EP (2) | EP3490586B1 (enExample) |
| JP (1) | JP7181855B2 (enExample) |
| CN (1) | CN109789181A (enExample) |
| CA (1) | CA3034566A1 (enExample) |
| WO (1) | WO2018022844A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
| CN117603949A (zh) * | 2019-03-19 | 2024-02-27 | 杰特创新股份有限公司 | 因子ix变体及其在治疗中的用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080102115A1 (en) * | 2006-06-19 | 2008-05-01 | Jorge Oyhenart | Modified coagulation factor IX polypeptides and use thereof for treatment |
| CN103282491A (zh) * | 2010-11-03 | 2013-09-04 | 催化剂生物科学公司 | 修饰的因子ix多肽及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX336958B (es) | 2005-11-15 | 2016-02-05 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
| EP2213733A3 (en) | 2006-05-24 | 2010-12-29 | Novo Nordisk Health Care AG | Factor IX analogues having prolonged in vivo half life |
| US7968683B1 (en) | 2008-05-07 | 2011-06-28 | Schering Corporation | Factor IXa crystals, related complexes and methods |
| AU2010278721A1 (en) | 2009-07-31 | 2012-02-16 | Bayer Healthcare Llc | Modified factor IX polypeptides and uses thereof |
| EP2760887B1 (en) | 2011-09-30 | 2024-10-23 | The Children's Hospital of Philadelphia | Compositions and methods for modulating hemostasis |
| US10676731B2 (en) | 2014-08-19 | 2020-06-09 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor IX function |
-
2017
- 2017-07-27 WO PCT/US2017/044104 patent/WO2018022844A2/en not_active Ceased
- 2017-07-27 EP EP17835248.0A patent/EP3490586B1/en active Active
- 2017-07-27 EP EP25157940.5A patent/EP4566666A3/en active Pending
- 2017-07-27 CN CN201780059441.0A patent/CN109789181A/zh active Pending
- 2017-07-27 CA CA3034566A patent/CA3034566A1/en active Pending
- 2017-07-27 US US16/320,137 patent/US11708570B2/en active Active
- 2017-07-27 JP JP2019504782A patent/JP7181855B2/ja active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080102115A1 (en) * | 2006-06-19 | 2008-05-01 | Jorge Oyhenart | Modified coagulation factor IX polypeptides and use thereof for treatment |
| CN103282491A (zh) * | 2010-11-03 | 2013-09-04 | 催化剂生物科学公司 | 修饰的因子ix多肽及其用途 |
Non-Patent Citations (1)
| Title |
|---|
| PAUL E. MONAHAN等: "employing a gain-of-funcition Factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy:preclinical evaluation supporting an ongoing adeno-associated virus clinical trial", 《HUMAN GENE THERAPY》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20200248161A1 (en) | 2020-08-06 |
| WO2018022844A2 (en) | 2018-02-01 |
| EP3490586A2 (en) | 2019-06-05 |
| CA3034566A1 (en) | 2018-02-01 |
| EP4566666A3 (en) | 2025-09-17 |
| EP3490586B1 (en) | 2025-03-26 |
| JP2019525764A (ja) | 2019-09-12 |
| JP7181855B2 (ja) | 2022-12-01 |
| EP4566666A2 (en) | 2025-06-11 |
| US11708570B2 (en) | 2023-07-25 |
| WO2018022844A3 (en) | 2019-04-18 |
| EP3490586A4 (en) | 2020-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9670267B2 (en) | Compositions and methods for enhancing coagulation factor VIII function | |
| US10106786B2 (en) | Compositions and methods for modulating hemostasis | |
| KR20120061898A (ko) | 출혈성 장애의 치료요법 및 예방 치료에 있어서의 비정맥내 투여를 위한 알부민 융합 응고 인자 | |
| CN113301911B (zh) | 用于调节因子viii功能的组合物和方法 | |
| CN109789181A (zh) | 用于调节因子ix功能的组合物和方法 | |
| MX2008006313A (es) | Metodos y composiciones para modular la hemostasia. | |
| US10676731B2 (en) | Compositions and methods for modulating factor IX function | |
| US20220259287A1 (en) | Single chain factor viii molecule | |
| AU2020242945B2 (en) | Factor IX variants and uses thereof in therapy | |
| US20230250412A1 (en) | Compositions and Methods for Modulating Factor IX Function | |
| CN120322246A (zh) | 用于调节因子viii功能的组合物和方法 | |
| US20210163575A1 (en) | Factor viii mutant expression vector with enhanced protein expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190521 |
|
| WD01 | Invention patent application deemed withdrawn after publication |